The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease
Open accessAbstract
Background Hypertriglyceridemia is associated with increased remnant-like particle cholesterol (RLP-C) and triglycerides in LDL (LDL-TG). Recent studies have focused on atherogenicity of RLP-C, with few data on LDL-TG. Objectives We examined associations of RLP-C and LDL-TG with incident cardiovascular disease (CVD) events and genetic variants in the Atherosclerosis Risk in Communities study. Methods Fasting plasma RLP-C and LDL-TG levels were measured in 9334 men and women without prevalent CVD. Participants were followed for incident CVD events (coronary heart disease [CHD] and ischemic stroke) for up to 16 years. Associations between LDL-TG and RLP-C levels and genetic variants were assessed by whole exome sequencing using single-variant analysis for common variants and gene-based burden tests for rare variants; both an unbiased and a candidate gene approach were explored Results RLP-C and LDL-TG levels were correlated with triglyceride levels (r=0.85 and r=0.64, p<0.0001). In minimally adjusted analyses, RLP-C and LDL-TG were associated with CVD risk, but in models adjusted for traditional risk factors including lipids, only LDL-TG was associated with incident CHD (hazard ratio [HR] 1.28, 95% confidence interval [CI] 1.10–1.50) and stroke (HR 1.47, 95% CI 1.13–1.92). A common APOE variant, rs7412, had the strongest association with LDL-TG and RLP-C (p<5×10−8). Conclusions RLP-C and LDL-TG levels were predictive of CVD and associated with APOE variants. LDL-TG may represent a marker of dysfunctional remnant lipoprotein metabolism associated with increased CVD risk. Further research is needed to determine whether LDL-TG plays a causal role in CVD and may be a target for therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Self-citationNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981 · cited 1×
“Previous studies also suggest a protective effect of APOE ε2 on atherosclerosis (46,47), despite the association between apoE2/2 and type III hyperlipoproteinemia (46), which is characterized by accumulated remnant lipoproteins with resulting increased blood TG and cholesterol levels.”
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 3×
“(93) Count: (5,563) (304) (1,289) (2,443) (251) 4”
Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Hypertriglyceridemia as a cardiovascular risk factor
Austin, M. A., Hokanson, J. E., & Edwards, K. L. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00031-9 · Cited by 1,066 · cited 3×
“(93) Count: (5,563) (304) (1,289) (2,443) (251) 4”
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 1×
“ApoCIII inhibits lipolysis by LPL and can delay clearance of atherogenic lipoproteins (35).”
Apolipoprotein E structure: insights into function
Hatters, D. M., Peters-Libeu, C. A., & Weisgraber, K. H. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.06.008 · Cited by 583 · cited 1×
“The different relationships of RLP-C and LDL-TG with APOE ε2/2 may be explained in part by the low affinity of apoE2 for the LDL (apoB/E) receptor, potentially leading to delayed clearance of VLDL and chylomicron remnants (48).”
Shahar, E., Chambless, L. E., Rosamond, W. D., Boland, L. L., Ballantyne, C. M., McGovern, P. G., & Sharrett, A. R. (2003) · Stroke · doi:10.1161/01.str.0000057812.51734.ff · Cited by 325 · cited 1×
“Arterial disease may differ among vascular beds, particularly smaller arteries and arterioles (33).”
Self-citation
Cited by
Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease
Castañer, O., Pintó, X., Subirana, I., Amor, A. J., Ros, E., Hernáez, Á., Martínez-González, M. Á., Corella, D., Salas-Salvadó, J., Estruch, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.008 · Cited by 540
Duran, E. K., Aday, A. W., Cook, N. R., Buring, J. E., Ridker, P. M., & Pradhan, A. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.059 · Cited by 334
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation
Hoogeveen, R. C., & Ballantyne, C. M. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa252 · Cited by 307
Self-citationFasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk
Keirns, B. H., Sciarrillo, C. M., Koemel, N. A., & Emerson, S. R. (2021) · Journal of Nutritional Science · doi:10.1017/jns.2021.73 · Cited by 86
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia
Adiels, M., Taskinen, M., Björnson, E., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Sihlbom, C., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13744 · Cited by 55
“In addition, our results indicate that apoC-III also affects the removal of remnant particles, resulting in an accumulation of atherogenic remnant particles.(60,61) This may explain the improved postprandial lipemia and robust reduction of surrogate markers of remnant particles during liraglutide therapy.”
ResultTriglycerides and ASCVD risk reduction: recent insights and future directions
Hussain, A., Ballantyne, C. M., Saeed, A., & Virani, S. S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00846-8 · Cited by 57
Self-citationBjörnson, E., Packard, C. J., Adiels, M., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Lundbom, J., et al. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13017 · Cited by 46
Xiong, C.-C., Gao, F., Zhang, J.-H., Ruan, Y., Gao, T.-G., Cai, J.-Y., & Liu, S.-F. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.131946 · Cited by 39
Remnant lipoproteins and atherosclerotic cardiovascular disease
Tada, H., Nohara, A., Inazu, A., Mabuchi, H., & Kawashiri, M.-A. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.12.014 · Cited by 37
Remnant cholesterol and long-term incidence of death in coronary artery disease patients
Drexel, H., Mader, A., Larcher, B., Festa, A., Vonbank, A., Fraunberger, P., Leiherer, A., & Saely, C. H. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.119048 · Cited by 17
Hypertriglyceridemia: molecular and genetic landscapes
Scicchitano, P., Amati, F., Ciccone, M. M., D’Ascenzi, F., Imbalzano, E., Liga, R., Paolillo, S., Pastore, M. C., Rinaldi, A., Mattioli, A. V., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126364 · Cited by 13
“Specifically, while FHT is mostly related to an increased production of VLDL particles from the hepatocytes, FCH is mainly characterized by the dramatic reduction in the clearance of remnants lipoproteins, which might promote atherosclerosis progression [59].”
BackgroundJia, Y.-P., Wang, J.-M., Lyu, J.-Q., Yang, H.-H., Miao, M.-Y., Wang, X., Wan, Z.-X., Zheng, Y., Qin, L.-Q., Li, F.-R., et al. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100653 · Cited by 10
Gupta, K., Hirsch, J. R., Kalsi, J., Patel, V., Gad, M. M., & Virani, S. S. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01079-7 · Cited by 9
Self-citation
Metadata
- Authors
- Saeed, A., Feofanova, E. V., Yu, B., Sun, W., Virani, S. S., Nambi, V., Coresh, J., Guild, C. S., Boerwinkle, E., Ballantyne, C. M., & Hoogeveen, R. C.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2018-07
- Volume
- 72
- Issue
- 2
- Pages
- 156-169
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2810548862
- Cited by
- 176
- References
- 15
- FWCI
- 15.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.